Literature DB >> 12565092

Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.

David J Schneider1, Howard C Herrmann, Nasser Lakkis, Frank Aguirre, Man Wai Lo, Kuo Chang Yin, Atul Aggarwal, Samer S Kabbani, Peter M DiBattiste.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12565092     DOI： 10.1016/s0002-9149(02)03163-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  10 in total

1.  Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.

Authors:  David J Schneider; Burton E Sobel
Journal:  J Thromb Thrombolysis       Date:  2008-07-08       Impact factor: 2.300

2.  Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Authors:  Dominick J Angiolillo; David J Schneider; Deepak L Bhatt; William J French; Matthew J Price; Jorge F Saucedo; Tamaz Shaburishvili; Kurt Huber; Jayne Prats; Tiepu Liu; Robert A Harrington; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 3.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

4.  Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

Authors:  Walter J Janse van Rensburg; Jan P Roodt; Seb Lamprecht; S Muriel Meiring; Philip N Badenhorst
Journal:  Clin Exp Med       Date:  2012-01-05       Impact factor: 3.984

Review 5.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 6.  Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

Authors:  David J Schneider
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

7.  Intracoronary versus intravenous high-dose bolus plus maintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction.

Authors:  Basar Candemir; Mustafa Kilickap; Ozgur Ulas Ozcan; Cansin Tulunay Kaya; Menekse Gerede; Aydan Ongun Ozdemir; Cagdas Ozdol; Deniz Kumbasar; Cetin Erol
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 8.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

9.  Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Authors:  Peter B Berger; Judson B Williams; Vic Hasselblad; Karen Chiswell; Karen S Pieper; Robert M Califf
Journal:  J Interv Cardiol       Date:  2013-02-05       Impact factor: 2.279

10.  Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.

Authors:  Waclaw Kochman; Slawomir Dobrzycki; Konrad S Nowak; Stefan Chlopicki; Pawel Kralisz; Przemyslaw Prokopczuk; Hanna Bachorzewska-Gajewska; Kamil Gugala; Maciej Niewada; Grzegorz Mezynski; Bogdan Poniatowski; Janusz Korecki; Wlodzimierz J Musial
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.